11/18
10:14 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
11/18
08:50 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
High
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
11/18
08:50 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
High
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
11/6
07:27 am
kymr
Rating for KYMR
Medium
Report
Rating for KYMR
11/6
07:27 am
kymr
Rating for KYMR
Medium
Report
Rating for KYMR
11/4
10:58 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
11/1
03:31 pm
kymr
Rating for KYMR
Low
Report
Rating for KYMR
11/1
03:31 pm
kymr
Rating for KYMR
Low
Report
Rating for KYMR
9/27
08:17 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
9/27
08:17 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
9/9
08:45 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock.
9/9
08:41 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
8/26
08:03 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $65.00 price target on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $65.00 price target on the stock.
8/26
08:03 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $65.00 price target on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $65.00 price target on the stock.
8/26
06:24 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
8/26
06:24 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR